After thirty, have you noticed that your hairline has started to move back? Especially for men, the hairline begins to recede in M-shape, and then at 40, the hair on the top of the scalp begins to thin, and finally develops into baldness.
You think hair loss is just old age? In fact, hair loss is also divided into three types: androgenic hair loss, alopecia areata and hair loss caused by anti-cancer drug treatment. Among them, androgenic alopecia (also known as seborrheic alopecia) has the highest incidence rate.
Androgenic alopecia can occur at any age after puberty, but most of them begin to appear around the age of 30. Globally, about half of men suffer from male baldness before the age of 50.
Source: Yaorong cloud database
According to the Yaorong cloud database, there are currently 147 global drug R & D models for hair loss indications, including 7 that have been listed, 2 that have submitted listing applications, 4 that are in phase III clinical research, and 78 that have been terminated, suspended and no follow-up progress reports.
Only two of the seven drugs listed have been approved by the US FDA, namely, finasteride for oral use and minoxidil for external use.
Minoxidil is available for men and women, while finasteride is exclusively for men. Today we mainly talk about finasteride.
Hair follicles in male hair loss area 5 α- The activity of reductase was significantly higher than that of non hair loss area. High level of dihydrotestosterone could make hair follicle atrophy, and gradually lead to shortening, thinning and falling off of hair growth period. Finasteride is also used in the treatment of androgen alopecia because it can reduce the level of dihydrotestosterone.
Finasteride was first used to treat benign prostatic hyperplasia. Later, research found that it had a significant effect on hair loss, so it was gradually used to treat hair loss. Generally, the treatment of male hair loss needs to be used for 6-8 months to achieve the ideal effect.
However, the drug has three poisons. It was previously reported that finasteride tablets would lead to persistent dysfunction and depression risk in patients, but suicide was not mentioned. In 2017, the "post finasteride Syndrome Foundation" made a request to the US FDA, asking MSD to either stop selling finasteride or inform patients of the side effects after use.
On June 10, the US FDA refused the request to "remove finasteride tablets and their generic drugs" on the ground that "no reasonable evidence has been provided" to prove that there is a causal relationship between finasteride tablets and persistent dysfunction, depression or suicide, but asked MSD to inform the patients that taking the drug will lead to suicidal behavior.
In fact, as early as 2009, according to more than 200 reports of depression and suicide among men taking finasteride tablets, MSD knew that finasteride tablets had side effects of depression and suicide. At present, FDA has received more than 700 reports on suicidal thoughts and behaviors caused by taking finasteride tablets.
Therefore, men with hair loss should pay attention to the side effects of finasteride tablets according to the doctor's advice.
